Inovio Pharma (INO) Stock Price, Quote & News

Company Profile

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline inclu...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 440 4200

Website: www.inovio.com

Address:

660 West Germantown Pike, Suite 110, Plymouth Meeting, United States

MoneyGroupLLC Oct. 25 at 5:05 PM

Enter: $INO Calls Strike Price: $4 Expiry Date: NOV 14 2025 Buy in Price: $0.05 - $1.00 Sell Price: $0.11 Profit : +129% (Turn every $1 into $2.29) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/

0 · Reply

Brianrasero Oct. 25 at 4:28 PM

$INO This week there’s been good news about Inovio regarding vaccine results. It should go up this coming week, right? Will we be able to break 2.6? Let’s go, team!

0 · Reply

RioeTheCuck Oct. 25 at 3:10 PM

$INO this pile of garbage will never be bought out. The reason being insiders have no incentive to do so cause they own virtually 0% of the company. They only make money by selling stock and paying their salaries. Rinse and repeat. People who buy shares in this company are mentally challenged

0 · Reply

Lookingdown Oct. 25 at 2:36 PM

$INO lots of findings today in my 💪💎👇 Safety, tolerability, and immunogenicity of INO-4500, a synthetic DNA-based vaccine against Lassa virus, in a phase 1b clinical trial in healthy Ghanaian adults October 23, 2025 https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1658549/full

0 · Reply

Lookingdown Oct. 25 at 2:31 PM

$INO Safety, Tolerability, and Immunogenicity of a DNA-based Vaccine (INO-4700) against Middle East Respiratory Syndrome Coronavirus: Phase 2a Study in Healthy Volunteers October 24, 2025 https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1662923/full

0 · Reply

Lookingdown Oct. 25 at 2:20 PM

$INO Nice mention of VGX-3100 in this scientific article 👇😉😎💪💎👇 "DNA-based vaccines, particularly VGX-3100, showed the most consistent results, whereas several protein- or vector-based approaches demonstrated variable outcomes" Advances in Therapeutic Vaccines Against HPV: A Review of Human Clinical Trials October 25, 2025 https://www.mdpi.com/1718-7729/32/11/600

2 · Reply

LiquidThetaLEAPS Oct. 25 at 2:13 PM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $INO Current Share Price: $2.33 Contracts: $INO May 15, 2026 $3 Calls Scale in: $0.36- $0.44 Scale out: $0.56-$0.72 Can Easily Capture: 60% ROI Blended DTE: 202 Days | Join Elites here: https://liquidtheta.com

0 · Reply

INOVIO Oct. 24 at 7:56 PM

$INO Looking good! Heading for a strong close.

0 · Reply

RioeTheCuck Oct. 24 at 7:19 PM

$INO I agree. My guess is this dogshit management team will blame government shutdown for the inevitable delay to the bla. They will continue the bla charade as long as they legally can and raise as much cash as possible. They could not give 2 shits about the stock price. That’s why insiders own literally 0 shares that they went into their own pocket for. they will raise at $1 or less if that’s what gets the job done for them

1 · Reply

rioe Oct. 24 at 4:18 PM

$INO Volume is picking up, good bid size! Hopefully a breakout. 🚀🚀

1 · Reply

INOVIO to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference

Oct 21, 2025, 8:05 AM EDT - 4 days ago

Clinical Proof-of-Concept Data for DNA-Encoded Monoclonal Antibodies (DMAbs) Published in Nature Medicine

Oct 2, 2025, 8:05 AM EDT - 23 days ago

INOVIO Reports Inducement Grant Under Inducement Plan

Sep 25, 2025, 8:05 AM EDT - 4 weeks ago

INOVIO to Participate in Upcoming Scientific Conferences

Sep 5, 2025, 9:37 AM EDT - 7 weeks ago

Inovio Pharmaceuticals, Inc. (INO) Presents At H.C. Wainwright 27th Annual Global Investment Conference (Transcript)

Aug 26, 2025, 8:05 AM EDT - 2 months ago

INOVIO to Begin Rolling Submission of BLA for INO-3107 for the Treatment of RRP in Adults

Aug 25, 2025, 8:05 AM EDT - 2 months ago

INOVIO to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 13, 2025, 3:26 AM EDT - 2 months ago

Inovio Pharmaceuticals, Inc. (INO) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:05 PM EDT - 2 months ago

INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 11, 2025, 8:05 AM EDT - 2 months ago

Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP)

Aug 4, 2025, 4:05 PM EDT - 2 months ago

INOVIO to Report Second Quarter 2025 Financial Results on August 12, 2025

Jul 7, 2025, 4:05 PM EDT - 3 months ago

INOVIO to Present at Upcoming Scientific Conference

Jul 3, 2025, 7:30 AM EDT - 4 months ago

INOVIO Announces Pricing of $25 Million Public Offering

Jul 2, 2025, 4:16 PM EDT - 4 months ago

INOVIO Announces Proposed Public Offering

Jul 1, 2025, 7:00 AM EDT - 4 months ago

Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development

May 13, 2025, 7:05 PM EDT - 5 months ago

Inovio Pharmaceuticals, Inc. (INO) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:05 PM EDT - 5 months ago

INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 9, 2025, 7:37 PM EDT - 6 months ago

Inovio Pharmaceuticals, Inc. (INO) Citizens JMP Life Sciences Conference (Transcript)

Apr 30, 2025, 8:05 AM EDT - 6 months ago

INOVIO to Present at Upcoming Scientific and Investor Conferences

Apr 29, 2025, 8:05 AM EDT - 6 months ago

INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025

Apr 9, 2025, 8:05 AM EDT - 7 months ago

INOVIO to Present at Upcoming Scientific Conferences

Mar 18, 2025, 8:48 PM EDT - 7 months ago

Inovio Pharmaceuticals, Inc. (INO) Q4 2024 Earnings Call Transcript

Mar 18, 2025, 4:05 PM EDT - 7 months ago

INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Mar 13, 2025, 6:15 PM EDT - 8 months ago

INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19

Mar 12, 2025, 12:55 PM EDT - 8 months ago

INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025

Feb 12, 2025, 5:39 PM EST - 9 months ago

Inovio Pharmaceuticals Inc (INO) Oppenheimer 35th Annual Healthcare Life Sciences Conference (Transcript)

Feb 12, 2025, 8:00 AM EST - 9 months ago

Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications

Feb 10, 2025, 8:05 AM EST - 9 months ago

Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference

Jan 29, 2025, 4:14 PM EST - 9 months ago

INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 9, 2025, 8:04 AM EST - 10 months ago

INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments

Jan 6, 2025, 7:19 AM EST - 10 months ago

Top 3 Health Care Stocks That Could Blast Off This Month

OTLK RCKT

Dec 13, 2024, 2:10 PM EST - 11 months ago

Gold Down Over 1%; Inovio Pharmaceuticals Shares Plummet

Dec 13, 2024, 7:00 AM EST - 11 months ago

INOVIO Announces Pricing of $30 Million Public Offering

Dec 3, 2024, 8:00 AM EST - 11 months ago

New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial

Nov 15, 2024, 11:21 AM EST - 1 year ago

European And US Vaccine Stocks Are Under Pressure - Here's WHy

AZN BNTX GSK MRK SNY VALN

Nov 14, 2024, 7:53 PM EST - 1 year ago

Inovio Pharmaceuticals, Inc. (INO) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 4:05 PM EST - 1 year ago

INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 13, 2024, 8:00 AM EST - 1 year ago

Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial

Nov 6, 2024, 8:00 AM EST - 1 year ago

INOVIO to Report Third Quarter 2024 Financial Results on November 14, 2024

Oct 21, 2024, 8:00 AM EDT - 1 year ago

INOVIO Announces New Data at Scientific Conferences for Lead Candidate, INO-3107, as a Potential Treatment for RRP

Oct 2, 2024, 4:15 PM EDT - 1 year ago

INOVIO Reports Inducement Grants Under Inducement Plan

Aug 9, 2024, 3:32 AM EDT - 1 year ago

Inovio Pharmaceuticals, Inc. (INO) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:05 PM EDT - 1 year ago

INOVIO Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Jul 25, 2024, 4:05 PM EDT - 1 year ago

Inovio Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107

Jul 25, 2024, 8:00 AM EDT - 1 year ago

INOVIO to Report Second Quarter 2024 Financial Results on August 8, 2024

Jul 11, 2024, 8:00 AM EDT - 1 year ago

INO-3107 Awarded the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway

Jul 2, 2024, 4:05 PM EDT - 1 year ago

INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer

Jul 1, 2024, 8:00 AM EDT - 1 year ago

INOVIO Added to Russell 2000® Index Effective July 1, 2024

Jun 4, 2024, 8:00 AM EDT - 1 year ago

INOVIO to Participate in Virtual Fireside Chat Hosted by Stephens Inc.

May 20, 2024, 4:31 PM EDT - 1 year ago

Inovio Pharmaceuticals, Inc. (INO) H.C. Wainwright 2nd Annual BioConnect Investor Conference (Transcript)

MoneyGroupLLC Oct. 25 at 5:05 PM

0 · Reply

Brianrasero Oct. 25 at 4:28 PM

$INO This week there’s been good news about Inovio regarding vaccine results. It should go up this coming week, right? Will we be able to break 2.6? Let’s go, team!

0 · Reply

RioeTheCuck Oct. 25 at 3:10 PM

0 · Reply

Lookingdown Oct. 25 at 2:36 PM

0 · Reply

Lookingdown Oct. 25 at 2:31 PM

0 · Reply

Lookingdown Oct. 25 at 2:20 PM

2 · Reply

LiquidThetaLEAPS Oct. 25 at 2:13 PM

0 · Reply

INOVIO Oct. 24 at 7:56 PM

$INO Looking good! Heading for a strong close.

0 · Reply

RioeTheCuck Oct. 24 at 7:19 PM

1 · Reply

rioe Oct. 24 at 4:18 PM

$INO Volume is picking up, good bid size! Hopefully a breakout. 🚀🚀

1 · Reply

RioeTheCuck Oct. 24 at 3:46 PM

$INO big volume again. That ass hat Robert must be buying more. Lol

0 · Reply

MoneyGroupLLC Oct. 24 at 3:10 PM

Enter: $INO NOV 14 2025 $4 CALLS Buy in Price: $0.05 - $0.90 Take Profit: $0.09 Stop Bleeding: $0.04 ROI Potential: 79% https://moneygroup.us/

0 · Reply

tau72 Oct. 24 at 2:33 PM

$INO Still waiting for device approval and BLA acceptance from FDA...and still holding large chunk of shares Need AZN to buy this out at $30 per share by Dec next year....

1 · Reply

RioeTheCuck Oct. 24 at 2:26 PM

$INO Robert is delusional and is trying to turn Inovio into a meme stock. It’s truly pathetic. Especially from someone who claims to be a professional institutional investor.

1 · Reply

Stormra Oct. 24 at 1:57 PM

$MBRX https://www.tipranks.com/news/ratings/moleculin-biotechs-promising-drug-pipeline-and-strategic-expansion-justify-buy-rating-ratings $INO $TRNR $AREB

0 · Reply

dogbone98 Oct. 24 at 12:56 PM

$INO Just curious- if 3107 gets approval, what is the financial forecast? What is cost of product, gross margin, estimated yearly sales projection, BE analysis, etc.? If you say $100 share price, that price has to be tied to profitability potential, so how do you arrive at that figure? What is $100/share based on, other than a GIF of a rocket ship?

1 · Reply

GorillaofWallStreet Oct. 24 at 12:49 PM

$INO Blocked again by the infamous serial pumper and cry baby, RIOE

0 · Reply

Lookingdown Oct. 24 at 12:26 PM

$INO Good morning everyone. I am Loving the view, the Tranquility that comes along with it and knowing what I know having little oh INO in my portfolio. Share price might look a bit discouraging now but its going up in a BIG way. Stay Tuned.. Just my little oh opinion.. Just saying. Do your own research for you newbies. I have PLENTY of info and scientific articles to see!! Just take a peek. 😉😎😊💪💎🫶

7 · Reply

joeddie23 Oct. 24 at 10:53 AM

$INO I w always thought we would end up here https://www.linkedin.com/posts/national-vaccine-institute_nvi-strengthens-vaccine-collaboration-with-activity-7387424131153190914-jR1A?utm_source=share&utm_medium=member_ios&rcm=ACoAAAZX2HEB62sKQKSqjmfYavwqK_8X09LfOBc

0 · Reply

updownsides Oct. 24 at 4:08 AM

$INO Cellectra and now follow-up data compromised by alternative therapy. Adds to the CRL odds. Now standing at 125%.

0 · Reply

Lookingdown Oct. 24 at 1:10 AM

$INO This grabbed my attention 😉👇 "The emergence of these gene therapies is a godsend for patients with rare diseases, offering them hope for a cure." https://www.forwardpathway.com/269405

0 · Reply

updownsides Oct. 24 at 1:01 AM

$INO

0 · Reply

Market Cap	119.57M
Revenue (ttm)	220,000.00
Net Income (ttm)	-107.25M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-48,750.00%
Debt to Equity Ratio	0.00

Volume	628,100
Avg Vol	1,656,514
Day's Range	N/A - N/A
Shares Out	53.14M
Stochastic %K	28%
Beta	1.65
Analysts	Strong Sell
Price Target	$7.47